The Patented Medicine Prices Review Board (PMPRB) has released its CompassRx 2017/18 Annual Public Drug Plan Expenditure Report and related news release reporting various statistics regarding prescription drug expenditures by Canadian public drug plans. The report indicates that prescription drug expenditure by public plans increased by 7.4% to C$11.4 billion in 2017-18.
Further, on 14 August 2019 the PMPRB announced the release of the latest edition of its Generics360 report, which reported that:
- generic drugs prices have dropped significantly in recent years as a result of government initiatives; and
- the most recent agreement between the pan-Canadian Pharmaceutical Alliance and the Canadian Generic Pharmaceutical Alliance brought Canadian generic prices more closely in line with international prices.
This article was first published by the International Law Office, a premium online legal update service for major companies and law firms worldwide. Register for a free subscription.
